Showing 1 - 7 results of 7 for search 'Martin Regueira, P', query time: 0.04s
Refine Results
-
1
Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra... by DiNardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Bluemmert, I, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Published 2021Conference item -
2
Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A... by DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Published 2021Conference item -
3
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, p... by DiNardo, CD, Schuh, AC, Stein, EM, Montesinos, P, Wei, AH, de Botton, S, Zeidan, AM, Fathi, AT, Kantarjian, HM, Bennett, JM, Frattini, MG, Martin-Regueira, P, Lersch, F, Gong, J, Hasan, M, Vyas, P, Döhner, H
Published 2021Journal article -
4
AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib... by DiNardo, CD, de Botton, S, Risueño, A, Schuh, AC, Löwenberg, B, Kim, HJ, Vyas, P, Wei, AH, Stein, EM, Döhner, H, Fathi, AT, Martin-Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Published 2022Conference item -
5
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemi... by Dinardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Chen, C, Lord-Bessen, J, Yu, P, Shi, L, Guo, S, Bluemmert, I, Yu, X, Hasan, M, Martin Regueira, P, De Botton, S
Published 2022Journal article -
6
A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AM... by Papayannidis, C, DiNardo, C, Montesinos, P, Schuh, A, Vyas, P, Wei, A, Ommen, H, Semochkin, S, Kim, H, Larson, R, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, M, Doronin, V, Dohner, H, Fathi, A, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Published 2021Conference item -
7
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial by de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Döhner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD
Published 2022Journal article